首页/数据集/Chromosomal deletion and chromatin remodeling Drive ABT-199 Resistance in B-cell Lymphomas. Chromosomal deletion and chromatin remodeling Drive ABT-199 Resistance in B-cell Lymphomas

Chromosomal deletion and chromatin remodeling Drive ABT-199 Resistance in B-cell Lymphomas. Chromosomal deletion and chromatin remodeling Drive ABT-199 Resistance in B-cell Lymphomas

NIAID Data Ecosystem2026-03-10 收录

癌细胞耐药性

B细胞淋巴瘤

数据链接：

https://www.ncbi.nlm.nih.gov/bioproject/PRJNA477350 数据链接链接失效反馈

官方服务：

资源简介：

This SuperSeries is composed of the SubSeries listed below. Overall design: Refer to individual Series

应用场景：

创建时间：

2018-06-21

癌细胞耐药性

上皮-间质转化调控

The resistance of cancer cells to therapy is responsible for the death of most cancer patients. Epithelial-to-mesenchymal transition (EMT) has been associated with resistance to therapy in different c

NIAID Data Ecosystem100

RNA-seq profiling of A549 cells with sgRNA knockouts that confer prexasertib resistance

癌细胞耐药性

转录组药物反应

A549 cells with FOXM1 or LIN54 sgRNA knockout, which confers resistance to the CHK1 inhibitor prexasertib, were generated. These cells and control (empty vector) cells were synchronized in S phase, re

NIAID Data Ecosystem60

IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy

癌细胞耐药性

抗EGFR治疗

Stochastic transition of cancer cells between drug-sensitive and drug-tolerant persister phenotypes has been proposed to play a key role in non-genetic resistance to therapy. Yet, we show here that ca

NIAID Data Ecosystem50

Overcoming Drug Resistance in Chronic Myeloid Leukemia: Rational Development of Druggable Molecular Glue Degraders

癌细胞耐药性

分子胶降解剂

Overcoming drug resistance remains a major challenge in targeted therapy. Molecular glue degraders offer a promising solution, but their discovery has been largely serendipitous, limiting systematic d

国家人口健康科学数据中心70

ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis. ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis

癌细胞耐药性

ZBP1

A disappointingly small proportion (10-30%) of patients with cancer show lasting responses to immune checkpoint blockade (ICB)-based monotherapies. The RNA-editing enzyme ADAR1 is an emerging determin

NIAID Data Ecosystem60

Chromosomal deletion and chromatin remodeling Drive ABT-199 Resistance in B-cell Lymphomas. Chromosomal deletion and chromatin remodeling Drive ABT-199 Resistance in B-cell Lymphomas

资源简介：

相关数据集